


Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) ~~The use~~ A method of using
a compound of formula (I)



(I)

wherein

(i) R¹ and R² are the same or different and are selected from H, -CH₂-O-R⁵, -CH₂-O-SO₂-R⁵, -CH₂-S-R⁵, -CH₂-NR⁴R⁵, -CH₂-O-CO-R⁵, -CH₂-O-CO-NR⁴R⁵ and -CH₂-O-CO-OR⁵;

R³ is =O, =S or =NR⁵;

R⁴ and R⁵ are the same or different and are selected from H; substituted or non-substituted, unbranched or branched, saturated or unsaturated C₃-C₁₂ cycloalkyl or C₁-C₁₀ alkyl; substituted or non-substituted benzyl; substituted or non-substituted mono- or bicyclic aryl;

substituted or non-substituted mono-, bi- or tricyclic C1-C10 heteroaryl or non-aromatic C1-C10 heterocyclyl wherein the heteroatoms are independently selected from N, O and S; or R^4 and R^5 in $-\text{CH}_2-\text{NR}^4\text{R}^5$ are bonded together and form, together with the nitrogen atom to which they are bonded, a substituted or non-substituted non-aromatic C1-C10 mono- or bicyclic heterocyclyl optionally containing one or several further heteroatoms independently selected from N, O and S and optionally comprising one or several cyclic keto groups; with the proviso that when R^1 and R^2 are both $-\text{CH}_2-\text{OR}^5$ then R^5 is not H; and with the further proviso that when one of R^1 and R^2 is H and the other one is $-\text{CH}_2-\text{NR}^4\text{R}^5$, then R^4 and R^5 are not substituted or non-substituted monocyclic aryl; or

(ii) R^1 and R^2 together with the carbon atom to which they are bonded form a substituted or non-substituted cyclic carbonate;


wherein the substituents of the substituted groups are selected from unbranched or branched, saturated or unsaturated C3-C12 cycloalkyl or C1-C10 alkyl; halogen; mono- or bicyclic aryl; mono-, bi- or tricyclic C1-C10 heteroaryl and non-aromatic C1-C10 heterocyclyl wherein the heteroatoms are independently selected from N, O and S; C1-C10 alkyloxy; amino; C1-C10 alkylamino; COR^6 ; CONR^6R^7 ; and COOR^6 ;

R⁶ and R⁷ are the same or different and are selected from H; unbranched or branched, saturated or unsaturated C3-C12 cycloalkyl or C1-C10 alkyl; benzyl; mono- or bicyclic aryl; mono-, bi- or tricyclic heteroaryl or non-aromatic C1-C10 heterocyclyl wherein the hetero-atoms are independently selected from N, O and S; as well as of pharmaceutically acceptable salts or prodrugs thereof, ~~for preparing a medicament~~

for the treatment of a disorder selected from hyperproliferative diseases, autoimmune diseases and heart diseases by administering said compound in an effective amount for said disorder, to a patient in need thereof.

2. (Currently Amended) The ~~use~~ method according to claim 1, wherein the disorder is a cancer.

3. (Original) A compound of formula (I)



(I)

wherein

(i) R¹ and R² are the same or different and are selected from H, -CH₂-O-CO-R⁵,

$-\text{CH}_2-\text{O}-\text{CO}-\text{NR}^4\text{R}^5$ and $-\text{CH}_2-\text{O}-\text{CO}-\text{OR}^5$;

R^3 is $=\text{O}$, $=\text{S}$ or $=\text{NR}^5$;

R^4 and R^5 are the same or different and are selected from H;

substituted or non-substituted, unbranched or branched,

saturated or unsaturated C3-C12 cycloalkyl or C1-C10 alkyl;

substituted or non-substituted benzyl; substituted or non-

substituted mono- or bicyclic aryl;

substituted or non-substituted mono-, bi- or tricyclic C1-C10

heteroaryl or non-aromatic C1-C10 heterocyclyl wherein the

heteroatoms are independently selected from N, O and S; or

R^4 and R^5 in $-\text{CH}_2-\text{NR}^4\text{R}^5$ are bonded together and form, together

with the nitrogen atom to which they are bonded, a

substituted or non-substituted non-aromatic C1-C10 mono- or

bicyclic heterocyclyl optionally containing one or several

further heteroatoms independently selected from N, O and S and

optionally comprising one or several cyclic keto groups; with

the proviso that R^1 and R^2 are not both H; or

(ii) R^1 and R^2 together with the carbon atom to which they are

bonded form a substituted or non-substituted cyclic carbonate;

wherein the substituents of the substituted groups are

selected from unbranched or branched, saturated or unsaturated


C3-C12 cycloalkyl or C1-C10 alkyl; halogen; mono- or bicyclic

aryl; mono-, bi- or tricyclic C1-C10 heteroaryl or non-

aromatic C1-C10 heterocyclyl wherein the heteroatoms are

independently selected from N, O and S; C1-C10 alkyloxy; amino; C1-C10 alkylamino; COR⁶; CONR⁶R⁷; and COOR⁶; R⁶ and R⁷ are the same or different and are selected from H; unbranched or branched, saturated or unsaturated C3-C12 cycloalkyl or C1-C10 alkyl; benzyl; mono- or bicyclic aryl; mono-, bi- or tricyclic heteroaryl or non-aromatic C1-C10 heterocyclyl wherein the hetero-atoms are independently selected from N, O and S; as well as pharmaceutically acceptable salts or prodrugs of the compounds of formula (I).

4. (Original) A process for the preparation of a compound according to claim 3 by reacting a compound of formula (I)



(I)

wherein

R¹, R² and R³ are as defined in claim 3, provided that at least one of R¹ and R² is -CH₂OH; or

wherein both R^1 and R^2 are $-CH_2OH$ and R^3 is as defined in claim 3; under conditions suitable for transforming at least one of R^1 and R^2 into $-CH_2-O-CO-R^5$, $-CH_2-O-CO-NR^4R^5$ or $-CH_2-O-CO-OR^5$ wherein R^4 and R^5 are as defined in claim 3.

5. (Currently Amended) A compound according to claim 3 in a dosage form suitable for use as a medicament.

6. (Original) A pharmaceutical composition comprising a therapeutically effective amount of a compound according to claim 3, or a pharmaceutically acceptable salt or prodrug thereof, and at least one pharmaceutically acceptable excipient.


7. (Original) A pharmaceutical composition according to claim 6, comprising at least one further, pharmaceutically active compound.

8. (Currently Amended) A pharmaceutical composition according to claim 7, wherein the compound ~~according to claim 3~~ and the further active compounds provide a synergistic therapeutic effect.

9. (Original) A pharmaceutical composition according to claim 8, wherein the at least one further active compound *in vivo* is susceptible of reacting with glutathione.

10. (Currently Amended) A pharmaceutical composition according to any one of claims 7-9, wherein the further pharmaceutically active compound is selected from adriamycin, melphalan and cisplatin.

11. (Original) A method of treatment of a disease selected from hyperproliferative diseases, autoimmune diseases, and heart diseases by administration of a therapeutically effective amount of a compound of formula (I)



(I)

wherein

(i) R¹ and R² are the same or different and are selected from H, -CH₂-O-R⁵, -CH₂-O-SO₂-R⁵, -CH₂-S-R⁵, -CH₂-NR⁴R⁵, -CH₂-O-CO-R⁵, -CH₂-O-CO-NR⁴R⁵ and -CH₂-O-CO-OR⁵;

R³ is =O, =S or =NR⁵;

R⁴ and R⁵ are the same or different and are selected from H; substituted or non-substituted, unbranched or branched, saturated or unsaturated C₃-C₁₂ cycloalkyl or C₁-C₁₀ alkyl;

substituted or non-substituted benzyl; substituted or non-substituted mono- or bicyclic aryl; substituted or non-substituted mono-, bi- or tricyclic C1-C10 heteroaryl or non-aromatic C1-C10 heterocyclyl wherein the heteroatoms are independently selected from N, O and S; or

R^4 and R^5 in $-\text{CH}_2-\text{NR}^4\text{R}^5$ are bonded together and form, together with the nitrogen atom to which they are bonded, a substituted or non-substituted non-aromatic C1-C10 mono- or bicyclic heterocyclyl optionally containing one or several further heteroatoms independently selected from N, O and S and optionally comprising one or several cyclic keto groups; with the proviso that when R^1 and R^2 are both $-\text{CH}_2-\text{OR}^5$ then R^5 is not H; and

with the further proviso that when one of R^1 and R^2 is H and the other one is $-\text{CH}_2-\text{NR}^4\text{R}^5$, then R^4 and R^5 are not substituted or non-substituted monocyclic aryl; or

(ii) R^1 and R^2 together with the carbon atom to which they are bonded form a substituted or non-substituted cyclic carbonate; wherein the substituents of the substituted groups are selected from unbranched or branched, saturated or unsaturated C3-C12 cycloalkyl or C1-C10 alkyl; halogen; mono- or bicyclic aryl; mono-, bi- or tricyclic C1-C10 heteroaryl or non-aromatic C1-C10 heterocyclyl wherein the heteroatoms are

independently selected from N, O and S; C1-C10 alkyloxy; amino; C1-C10 alkylamino; COR⁶; CONR⁶R⁷; and COOR⁶; R⁶ and R⁷ are the same or different and are selected from H; unbranched or branched, saturated or unsaturated C3-C12 cycloalkyl or C1-C10 alkyl; benzyl; mono- or bicyclic aryl; mono-, bi- or tricyclic heteroaryl or non-aromatic C1-C10 heterocyclyl wherein the heteroatoms are independently selected from N, O and S; as well as of pharmaceutically acceptable salts or prodrugs thereof, to a patient in the need of such treatment.

12. (Original) The method according to claim 11 wherein the compound of formula (I) is administered together with a further, pharmaceutically active compound.

13. (Original) The method according to claim 12, wherein the compound of formula (I) and the further, pharmaceutically active compound are providing a synergistic effect in vivo.

14. (Original) The method according to the claim 13 wherein the further, pharmaceutically active compound in vivo is susceptible of reacting with glutathione.

15. (Currently Amended) The method according to any one of the claims 12-14, wherein the further

pharmaceutically active compound is selected from adriamycin,
melphalan, cisplatin.